Drug development is expensive and risky, and companies are always looking for smarter ways to manage costs. That’s where Chinese CROs come into the picture. Instead of building massive in-house labs, many global pharma companies now outsource preclinical studies to specialized providers in China. The rapid expansion of the China Preclinical CRO Market reflects strong demand for...